ClinicalTrials.gg
CompletedNCT01761526Updated Oct 20, 2014

Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects

A Phase 1 interventional study of Rotigotine transdermal patch in Healthy, sponsored by UCB BIOSCIENCES GmbH. Completed at 1 site in Germany. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-20.

Sponsored by UCB BIOSCIENCES GmbH (part of UCB S.A.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

To investigate the Pharmacokinetics (PK) of transdermally delivered Rotigotine in Japanese and Caucasian Female and Male Healthy Subjects.

02

Conditions studied

  • Healthy

Keywords

  • Rotigotine
  • Neupro
  • Japanese
  • Caucasian
  • Male
  • Female
  • Single dose
  • Pharmacokinetics
03

In context

Lead sponsor

UCB BIOSCIENCES GmbH is the lead sponsor of 21 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is healthy according to assessments done at eligibility assessment (medical history, physical examination, blood pressure, heart rate, (ECG), hematology, clinical chemistry, urinalysis)
  • Subject is of normal body-weight as determined by a ranging between 18 to 28 kg / m²
  • Subject is Japanese or Caucasian. Japanese subjects are born in Japan and left Japan not more than 10 years ago. Both parents of the Japanese subjects are 100 % Japanese

Exclusion criteria

Exclusion Criteria:

  • Subjects (females) without medically adequate (e.g. mechanical contraception (Intrauterine-Device IUD), sterilization, hysterectomy) or on lactation or pregnant women. Subjects with oral contraception or hormone replacement within 4 weeks prior to eligibility assessment
  • Subject has a history of chronic alcohol or drug abuse
  • Subject has a consumption of more than 20 g of alcohol / day (amount corresponds to 0.5 l of beer / day or 0.25 l of wine / day or 3 glasses (à 2 cl) of liquor / day
  • Subject has a allergy
  • Subject has a known or suspected drug in particular, to any component of the trial medication
  • Subject has any clinically significant abnormality in physical examination
  • Subject has a heart rate at rest less than 50 beats per minute (bpm) or more than 100 bpm
  • Subject has systolic blood pressure lower than 100 mmHg or higher than 145 mmHg or diastolic blood pressure higher than 95 mmHg or lower than 60 mmHg
  • Subject has an atopic or eczematous dermatitis and / or an active skin disease or skin tumors
  • Subject has a history of significant skin hypersensitivity to adhesives or other transdermal products or recent unresolved contact dermatitis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Rotigotine in Healthy Japanese

    * Rotigotine transdermal patch * Single dose application of 2 mg / 24 hours Rotigotine in Healthy Japanese subjects * Transdermal patch over 24 hours

    Drug: Rotigotine transdermal patch

  • Experimental
    Rotigotine in Caucasian

    * Rotigotine transdermal patch * Single-Dose application of 2 mg / 24 hours Rotigotine in healthy Caucasian subjects * Transdermal patch over 24 hours

    Drug: Rotigotine transdermal patch

Interventions

  • Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)

    Also known as: Neupro

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve (AUC) from zero up to the last measured concentration greater than the Lower Limit of Quantitation (LOQ) [AUC (0-t)] of unconjugated Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  2. Area under the concentration-time curve from zero up to the last measured concentration greater than the Lower Limit of Quantitation (LOQ) normalized [AUC (0-t)norm] of unconjugated Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  3. Maximum concentration in plasma [Cmax] of unconjugated Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  4. Maximum concentration in plasma normalized by body weight [Cmax,norm] of unconjugated Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  5. Area under the concentration-time curve from zero up to the last measured concentration greater than the Lower Limit of Quantitation (LOQ) [AUC (0-t)] of total Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  6. Maximum concentration in plasma [Cmax] of total Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  7. Maximum concentration in plasma normalized by body weight [Cmax,norm] of total Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  8. Area under the concentration-time curve from zero up to the last measured concentration greater than the Lower Limit of Quantitation (LOQ) [AUC (0-t)] of total Despropylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  9. Area under the concentration-time curve from zero up to the last measured concentration greater than the Lower Limit of Quantitation (LOQ) normalized by body weight [AUC (0-t)] of total Despropylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  10. Maximum concentration in plasma [Cmax] of total Despropylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  11. Maximum concentration in plasma normalized by body weight [Cmax,norm] of total Despropylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  12. Area under the concentration-time curve from zero up to the last measured concentration greater than the Lower Limit of Quantitation (LOQ) [AUC (0-t)] of total Desthienylethylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  13. Area under the concentration-time curve from zero up to the last measured concentration greater than the Lower Limit of Quantitation (LOQ) normalized by body weight [AUC (0-t)] of total Desthienylethylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  14. Maximum concentration in plasma [Cmax] of total Desthienylethylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  15. Maximum concentration in plasma normalized by body weight [Cmax, norm] of total Desthienylethylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

Secondary outcomes

  1. Terminal half-life [t1/2] of unconjugated Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  2. Time of maximum concentration [tmax] of unconjugated Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  3. Area under the concentration-time curve from zero to infinity [AUC (0-inf)] of unconjugated Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  4. Total body clearance (CL) of unconjugated Rotigotine normalized by body weight (BW) [CL/f/BW]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  5. Apparent volume of distribution of unconjugated Rotigotine normalized by body weight [Vz/f/BW]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  6. Amounts of unconjugated Rotigotine excreted in urine [Ae]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  7. Fraction of unconjugated Rotigotine excreted into urine [fe (% of dose)]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  8. Renal Clearance [CLR] of unconjugated Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  9. Terminal half-life [t1/2] of total Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  10. Time of maximum concentration [tmax] of total Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  11. Area under the concentration-time curve from zero to infinity [AUC (0-inf)] of total Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  12. Total body clearance of total Rotigotine normalized by body weight [CL/f/BW]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  13. Apparent volume of distribution normalized of total Rotigotine by body weight [Vz/f/BW]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  14. Amount of total Rotigotine excreted into urine [Ae]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  15. Fraction of total Rotigotine excreted into urine [fe (% of dose)]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  16. Renal clearance [CLR] of total Rotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  17. Terminal half-life [t1/2] of total Despropylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  18. Time of maximum concentration [tmax] of total Despropylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  19. Area under the concentration-time curve from zero to infinity [AUC (0-inf)] of total Despropylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  20. Total body clearance of total Despropylrotigotine normalized by body weight [CL/f/BW]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  21. Apparent volume of distribution of total Despropylrotigotine normalized by body weight [Vz/f/BW]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  22. Amount of total Despropylrotigotine excreted into urine [Ae]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  23. Fraction of total Despropylrotigotine excreted into urine [fe (% of dose)]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  24. Renal Clearance [CLR] of total Despropylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  25. Terminal half-life [t1/2] of total Desthienylethylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  26. Time of maximum concentration [tmax] of total Desthienylethylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  27. Area under the concentration-time curve from zero to infinity [AUC (0-inf)] of total Desthienylethylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  28. Total body clearance of total Desthienylethylrotigotine normalized by body weight [CL/f/BW]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  29. Apparent volume of distribution of total Desthienylethylrotigotine normalized by body weight [Vz/f/BW]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  30. Amount of total Desthienylethylrotigotine excreted into urine [Ae]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  31. Fraction of total Desthienylethylrotigotine excreted into urine [fe (%of dose)]

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

  32. Renal clearance [CLR] of total Desthienylethylrotigotine

    Blood sampling at 0 hours (Pre-Dose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours, and 60 hours Post-Dose

    Time frame: From Baseline (0 hours Pre-Dose) up to 60 hours Post-Dose

07

Study locations

1 site
  • 01
    Neuss, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002, a primary completion of Oct 2002 and a completion of Dec 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2013
First posted
Jan 4, 2013
Start
Oct 2002
Primary completionActual
Oct 2002
CompletionActual
Dec 2002
Last update
Oct 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01761526
Collaborators
Schwarz BioSciences GmbH, Alfred-Nobel-Str. 10, 40789 Monheim am Rhein
Responsible party
Sponsor
First posted
Jan 4, 2013
Start date
Oct 2002
Primary completion
Oct 2002
Completion
Dec 2002
Last update
Oct 20, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion